Spots Global Cancer Trial Database for Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
Official Title: A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Study ID: NCT00603668
Conditions
Interventions
Study Description
Brief Summary: This study will test different doses of anti-CD74 antibody in patients with NHL and/or CLL.
Detailed Description: Milatuzumab (hLL1, IMMU-115), a humanized anti-CD74 monoclonal antibody. Dose escalation will utilize 4 planned dose regimens with 4.0 or 8.0 mg/kg doses administered intravenously either twice weekly (days 1 and 4) or thrice weekly (days 1, 3 and 5) for 4 consecutive weeks. The four planned dose regimens will be labeled as dose level 1 to 4 corresponding to increasing levels of the total dose of milatuzumab.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
Georgetown University Hospital Lombardi Cancer Center, Washington, District of Columbia, United States
M. D. Anderson Cancer Center, Orlando, Florida, United States
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: William Wegener, MD, PhD
Affiliation: Gilead Sciences
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
